User profiles for "author:Kathleen M Darcy"
 | Kathleen M DarcyCOO, GYN-COE and WHIRC, Henry M Jackson Foundation for the Advancement for Military … Verified email at whirc.org Cited by 8495 |
A developmental atlas of rat mammary gland histology
PA Masso-Welch, KM Darcy, NC Stangle-Castor… - Journal of mammary …, 2000 - Springer
The mammary gland is a dynamic tissue that undergoes epithelial expansion and invasion
during puberty and cycles of branching and lobular morphogenesis, secretory differentiation …
during puberty and cycles of branching and lobular morphogenesis, secretory differentiation …
[HTML][HTML] Current approaches and challenges in managing and monitoring treatment response in ovarian cancer
CS Marcus, GL Maxwell, KM Darcy, CA Hamilton… - Journal of …, 2014 - ncbi.nlm.nih.gov
Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies.
Treatment of recurrent ovarian cancer remains a challenge despite advances in surgical and …
Treatment of recurrent ovarian cancer remains a challenge despite advances in surgical and …
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with …
MA Bookman, KM Darcy, D Clarke-Pearson… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal
antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu …
antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu …
[HTML][HTML] Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
C Aghajanian, MW Sill, KM Darcy, B Greer… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose Bevacizumab, a recombinant humanized monoclonal antibody against vascular
endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We …
endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We …
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study
GF Fleming, MW Sill, KM Darcy, DS McMeekin… - Gynecologic …, 2010 - Elsevier
PURPOSE: This study evaluated efficacy of single-agent trastuzumab against advanced or
recurrent HER2-positive endometrial carcinoma (EC), and explored predictors for HER2 …
recurrent HER2-positive endometrial carcinoma (EC), and explored predictors for HER2 …
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations …
RJ Schilder, MW Sill, X Chen, KM Darcy… - Clinical Cancer …, 2005 - AACR
Purpose: This phase II trial assessed the activity and tolerability of a daily oral dose of 500
mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent epithelial ovarian or …
mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent epithelial ovarian or …
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and …
K Behbakht, MW Sill, KM Darcy, SC Rubin… - Gynecologic …, 2011 - Elsevier
OBJECTIVE: Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal
cancer (EOC/PPC) have limited treatment options. AKT and PI3K pathway activation is …
cancer (EOC/PPC) have limited treatment options. AKT and PI3K pathway activation is …
[HTML][HTML] Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study
DS McMeekin, DL Tritchler, DE Cohn… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose The clinicopathologic significance of mismatch repair (MMR) defects in
endometrioid endometrial cancer (EEC) has not been definitively established. We undertook …
endometrioid endometrial cancer (EEC) has not been definitively established. We undertook …
Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
L Havrilesky, KM Darcy, H Hamdan… - Journal of clinical …, 2003 - ascopubs.org
Purpose: The prognostic significance of p53 mutations and overexpression in advanced
epithelial ovarian cancers was examined in primary tumors from 125 patients participating in …
epithelial ovarian cancers was examined in primary tumors from 125 patients participating in …
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic …
G Thomas, S Ali, FJP Hoebers, KM Darcy… - Gynecologic …, 2008 - Elsevier
PURPOSE: To determine whether maintaining HGB levels≥ 12.0 g/dL with recombinant
human erythropoietin (R-HUEPO) compared to “standard” treatment (transfusion for HGB≤ …
human erythropoietin (R-HUEPO) compared to “standard” treatment (transfusion for HGB≤ …